Literature DB >> 10580663

Clinical course of HTLV-I-associated uveitis.

K Nakao1, N Ohba, M Nakagawa, M Osame.   

Abstract

PURPOSE: To define the long-term clinical course and visual outcome of human T-cell lymphotrophic virus type I (HTLV-I)-associated uveitis (HAU).
METHODS: We reviewed the clinical data on 96 eyes of 70 patients, 26 men and 44 women, with HAU, with specific reference to recurrence of the disease and long-term visual outcome. The mean follow-up period was 83 months (range, 12-276 months).
RESULTS: The mean age of onset was 42.8 years (range, 7-78 years of age), with men presenting at a significantly younger age. Forty-seven patients had isolated HAU; in 10 patients, HTLV-I-associated myelopathy occurred before or after the onset of HAU; in 14 patients, hyperthyroidism had preceded HAU. A single episode of mild to moderate acute uveal inflammation with resolution in a few weeks or more occurred in 44 (62.9%) patients, and multiple episodes in 26 (37.1%), with a mean interval of 16 months (range, 1-250 months), which affected the same eye, fellow eye, or both. The majority of patients had favorable visual outcome at the last examination, whereas only a few patients suffered poor vision resulting from steroid cataract and retinochoroidal degeneration.
CONCLUSIONS: The clinical course of HAU is virtually benign and its visual outcome is favorable, although its recurrence is common. The uveitis is usually isolated and affects a portion of otherwise unremarkable HTLV-I carriers, but it may sometimes be manifest as a symptom of syndromic diseases such as HTLV-I-associated myelopathy or hyperthyroidism. This study describes for the first time cases of HAU that occurred many years before manifestation of HTLV-I-associated myelopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580663     DOI: 10.1016/s0021-5155(99)00099-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  4 in total

Review 1.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 2.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

3.  Clinical features of human T lymphotropic virus type 1-associated uveitis in Hokkaido, Japan.

Authors:  Satoru Kase; Kenichi Namba; Nobuyoshi Kitaichi; Daiju Iwata; Shigeaki Ohno; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2013-04-23       Impact factor: 2.447

4.  Neurological concomitants of uveitis.

Authors:  J R Smith; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.